Dyve Biosciences
PrivateCompany Overview
Dyve Biosciences is a biotechnology company that develops transdermal delivery therapies targeting acidic microenvironments in diseases such as cancer and immunological conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Dyve Biosciences Comparables
Compare Dyve Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Biotts | 76% | |
| Ategenos Pharmaceuticals | 65% | |
| Taisei Kako Co., Ltd. | 64% | |
Dyve Biosciences Funding Rounds
Historical fundraising activity
Market signals
Structured signals derived from secondary market and firmographic data.
- May 13, 2026
Monthly visitors increased 43% MoM.
- Jun 1, 2025
Monthly visitors increased 57% MoM.
Dyve Biosciences Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Dyve Biosciences's valuation, stock price, and market status.